# A Trial to Evaluate the Safety and Efficacy of NCR102 in Subjects With aGVHD

> **NCT06941350** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Nuwacell Biotechnologies Co., Ltd.** · enrollment: 24 (estimated)

## Conditions studied

- Acute Graft-versus-Host Disease

## Interventions

- **BIOLOGICAL:** NCR102 injection

## Key facts

- **NCT ID:** NCT06941350
- **Lead sponsor:** Nuwacell Biotechnologies Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-04-28
- **Primary completion:** 2026-10-30
- **Final completion:** 2027-05-30
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06941350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06941350, "A Trial to Evaluate the Safety and Efficacy of NCR102 in Subjects With aGVHD". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06941350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*